SCHEMBL2479480

SCHEMBL2479480

Cc1ccc(-n2nc(C(C)(C)COCc3ccccc3)cc2N)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
SMN1; SMN2 Q16637 6/20 0.45
MAPT P10636 4/20 0.45
ALDH1A1 P00352 2/20 0.45
STAT1 P42224 1/20 0.45
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
MAPK14 Q16539 3/20 0.42
MAPK1 P28482 1/20 0.42
HMGCR P04035 1/20 0.40
NPY5R Q15761 2/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
LMNA P02545 3/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13330976 0.80 NPC1 (0.43) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL2082879 0.77 MAPK14 (0.47) NPC1RAB9ASMN1; SMN2MAPTCYP1A2
SCHEMBL13532136 0.77 NPC1 (0.56) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL21439857 0.76 CDK8 (0.45) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
Hydrochloric Acid SCHEMBL3185615 0.76 NPC1 (0.55) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL3771713 0.76 NPC1 (0.51) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL366727 0.75 NPC1 (0.60) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
Hydrochloric Acid SCHEMBL1504021 0.74 NPC1 (0.58) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL3176111 0.74 HCK (0.40) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL1521591 0.73 CYP1A2 (0.46) NPC1RAB9ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370429-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2016-04-20 EP disclosed
US-8299074-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2012-10-30 US disclosed
CN-102333770-A P38 map kinase inhibitors RESPIVERT LTD 2012-01-25 CN disclosed
US-20110312963-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2011-12-22 US disclosed
EP-2370429-A1 P38 MAP KINASE INHIBITORS Respivert Limited (GB) 2011-10-05 EP disclosed
WO-2010067130-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312963-A1 P38 MAP KINASE INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 NPC1 2933/4885RAB9A 2492/4885SMN1; SMN2 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.